NTLA Q2 2023 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M-3.1% YoY

Gross Profit

-$102M-748.0% margin

Operating Income

-$132M-973.5% margin

Net Income

-$124M-909.8% margin

EPS (Diluted)

$-1.40

QoQ Revenue Growth

+7.8%

Cash Flow

Operating Cash Flow

-$90M

Free Cash Flow

-$95M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$218M

Stockholders' Equity

$1.1B

Cash & Equivalents

$172M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$14M	-3.1%
Gross Profit	-$102M	-$76M	-33.5%
Operating Income	-$132M	-$98M	-34.6%
Net Income	-$124M	-$101M	-22.8%